Y-mAbs Therapeutics (YMAB -3.4%) inks an agreement with
Memorial Sloan Kettering Cancer Center (MSK) and Massachusetts
Institute of Technology securing exclusive global rights to develop and
commercialize antibody constructs based on the SADA-BiDE (2-step
Self-Assembly and DisAssembly-Bispecific DOTA-Engaging antibody system)
Pre-targeted Radioimmunotherapy Platform developed at MSK.
The SADA technology uses a targeted payload
delivery method whereby antibody constructs assemble in large molecules
called tetramers that bind to tumor cells. A second infusion of a
radioactive payload binds to the constructs to radiate the tumor.
Financial terms are not disclosed.
https://seekingalpha.com/news/3560895-y-mabs-in-licenses-novel-antibody-technology-for-use-in-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.